The National Institute for Health and Care Excellence

‘Trojan horse’ treatment recommended for people with multiple myeloma

Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
The National Institute for Health and Care Excellence

Have your say on NICE’s adoption of the new EQ-5D-5L value set

We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of ...
National Institute for Health and Care Excellence

Subcutaneous spesolimab 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over (terminated appraisal)

NICE is unable to make a recommendation on subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalised pustular psoriasis flares in people 12 years and over. This is because the ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock HTG774 25 March 2026 25 March 2026 Percutaneous insertion of a catheter-based left ventricular ...
National Institute for Health and Care Excellence

Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils

Evidence-based recommendations on dupilumab (Dupixent) for add-on maintenance treatment of uncontrolled chronic obstructive pulmonary disease (COPD) with raised blood eosinophils in adults ...
National Institute for Health and Care Excellence

Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)

NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by myelodysplastic syndromes because BMS did not provide an evidence submission.
National Institute for Health and Care Excellence

Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer

This guidance has been updated and replaced by NICE technology appraisal guidance on pembrolizumab with pemetrexed and platinum chemotherapy for untreated ...
National Institute for Health and Care Excellence

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...
National Institute for Health and Care Excellence

Osteoarthritis in over 16s: diagnosis and management

This guideline covers the diagnosis, assessment and non-surgical management of osteoarthritis. It aims to improve management of osteoarthritis and the quality of life for people with osteoarthritis.
National Institute for Health and Care Excellence

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...
National Institute for Health and Care Excellence

Low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy

We have moved interventional procedures guidance 615 to become HealthTech guidance 472. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...